Agios Pharmaceuticals Inc (AGIO)

43.86
NASDAQ : Health Care
Prev Close 43.86
Day Low/High 0.00 / 0.00
52 Wk Low/High 33.50 / 115.39
Avg Volume 783.10K
Exchange NASDAQ
Shares Outstanding 37.92M
Market Cap 1.73B
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dr. Michael Rosenblatt Joins Flagship Ventures As Chief Medical Officer

Dr. Michael Rosenblatt Joins Flagship Ventures As Chief Medical Officer

New Position Created to Support Growing Clinical Research Programs Across Flagship's Start-up Ecosystem

Agios Pharmaceuticals (AGIO) Is Today's Dead Cat Bounce Stock

Agios Pharmaceuticals (AGIO) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Flagship Ventures Names Daniel McIntyre Partner

Flagship Ventures Names Daniel McIntyre Partner

Industry Veteran Assumes new position to lead strategic communication

AGIO Pharmacueticals (AGIO) Stock Up on Positive Drug Results

AGIO Pharmacueticals (AGIO) Stock Up on Positive Drug Results

AGIO Pharmacueticals (AGIO) announced positive results of it's anemia drug which led to an upgraded rating and increasing stock.

Trade-Ideas: Agios Pharmaceuticals (AGIO) Is Today's

Trade-Ideas: Agios Pharmaceuticals (AGIO) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Analysts' Actions -- Agios Pharma, Concho Resources, Occidental, Sprouts and More

Analysts' Actions -- Agios Pharma, Concho Resources, Occidental, Sprouts and More

Here are Monday's top research calls, including upgrades for Agios Pharmaceuticals and Concho Resources, and downgrades for Occidental Petroleum and Sprouts Farmers Market.

Agios Anemia Drug Data Hits the Mark and Raises Some Questions

Agios Anemia Drug Data Hits the Mark and Raises Some Questions

Agios Pharmaceuticals said its experimental drug AG-348 increased hemoglobin levels in nine of 18 patients with a rare, inherited form of anemia treated in a clinical trial.

Agios Pharmaceuticals (AGIO) Stock: Weak On High Volume Today

Agios Pharmaceuticals (AGIO) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate

Agios Pharmaceuticals (AGIO) Marked As A Dead Cat Bounce Stock

Agios Pharmaceuticals (AGIO) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "dead cat bounce" (down big yesterday but up big today) candidate

Agios Pharmaceuticals (AGIO) Is Today's Perilous Reversal Stock

Agios Pharmaceuticals (AGIO) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "perilous reversal" (up big yesterday but down big today) candidate

Agios Pharmaceuticals (AGIO) Weak On High Volume

Agios Pharmaceuticals (AGIO) Weak On High Volume

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate

Celgene, Agios Expand, Amend Cancer Drug Partnership

Celgene, Agios Expand, Amend Cancer Drug Partnership

Celgene is paying $200 million for development rights to early research Agios is conducting into new drug targets that alter the metabolism of immune cells to help kill cancer cells.

Agios Updates 2016 Financial Guidance

Agios Updates 2016 Financial Guidance

Perilous Reversal Watch: Agios Pharmaceuticals (AGIO)

Perilous Reversal Watch: Agios Pharmaceuticals (AGIO)

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a "perilous reversal" (up big yesterday but down big today) candidate

Weak On High Volume: Agios Pharmaceuticals (AGIO)

Weak On High Volume: Agios Pharmaceuticals (AGIO)

Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate

Jim Cramer's 'Mad Money' Recap: Short-Term Pain? Try Investing for Long-Term Gain

Jim Cramer's 'Mad Money' Recap: Short-Term Pain? Try Investing for Long-Term Gain

Timing is everything, and investing short term may keep you from opportunities, Cramer says.

Don't Buy Into This Kind of Bull

Risks far outweigh the possible rewards of buying into late bullishness.

Don't Buy Into This Kind of Bull

Risks far outweigh the possible rewards of buying into late bullishness.

Credit Suisse's 11 Positive 'Out on a Limb' Stock Ideas

Credit Suisse's 11 Positive 'Out on a Limb' Stock Ideas

Looking for some out-of-the-box investment ideas? Consider Credit Suisse's contrarian stock list.

5 Stocks That Could Be Toxic to Your Portfolio in 2016

5 Stocks That Could Be Toxic to Your Portfolio in 2016

It's time to unload these toxic stocks from your portfolio.